Barclays lowered the firm’s price target on Crispr Therapeutics to $59 from $67 and keeps an Equal Weight rating on the shares. The company’s Q2 update was largely incremental, with the focus maintained on the Casgevy launch, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
- Vertex Pharmaceuticals (NASDAQ:VRTX) Slides despite Raising Revenue Guidance
- CRSP Earnings this Week: How Will it Perform?
- JMP Securities healthcare analysts hold an analyst/industry conference call
- CRISPR Therapeutics Nears 52-Week Low. Time to Buy?